EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. · 2018
Read EGFR-TKIs resistance via EGFR-independent signaling pathways. by Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5817859.txt.
Description
Liu and co-authors review how lung cancers escape EGFR-blocking drugs without using EGFR itself. The review appeared in Molecular Cancer. Drugs such as gefitinib and erlotinib help patients whose tumors carry EGFR mutations. Most tumors still adapt and resume growth.
Resistance splits into two broad routes. New EGFR mutations like T790M block the drug directly. The review centers on the second route, bypass signaling. Other receptor kinases, such as MET and HER2, switch on and revive the PI3K/Akt and MAPK pathways. Faulty downstream parts can do the same job. The authors map each bypass track and the trials testing paired drugs against it.
Catalog record
| CREATOR | Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |